Skip to main content


Oligodendroglioma Workshop Attendees


NCI-CONNECT hosts meetings at NIH throughout the year to bring together worldwide leaders in neuro-oncology clinical care, basic science, and clinical research with advocacy partners. The meetings aim to advance knowledge and collaborations to discover better treatments for people with rare central nervous system (CNS) cancers.

2019 NCI-CONNECT and BTTC Meeting

April 29-30, 2019

The NCI-CONNECT and Brain Tumor Trials Collaborative (BTTC) Annual Meetings brought over 100 attendees across neuro-oncology specialties together to discuss CNS tumor clinical studies. Presentations and discussions included current studies and new clinical trial concepts that, in addition to measuring efficacy, incorporate patient quality of life and outcomes measures. The overall aim in each session was to ensure current and future studies will help effectively advance treatments for patients with gliomas and rare CNS cancers.

Read the meeting summary >

2018 NCI-CONNECT and BTTC Meeting

June 11-12, 2018

The inaugural NCI-CONNECT Meeting was held in conjunction with the BTTC Annual Meeting. The goal of the meetings was to bring together leaders in a collegial and collaborative environment to discuss current and future clinical trials for patients with malignant brain tumors, with a particular focus on rare CNS tumors. Attendees shared new clinical trial concepts that had both high levels of scientific merit and also incorporated measures of patient quality of life and outcomes.

Read the meeting summary >


NCI-CONNECT hosts and participates in tumor-specific workshops at NIH where experts across institutions studying rare brain and spine cancers and advocates can share knowledge and collaborate. The goal of these workshops is to identify areas of research, develop plans and designs for clinical trials, and facilitate collaboration.

Following each workshop, NCI-CONNECT will share information for healthcare providers and people living with these rare brain and spine cancers.

Histone Midline Glioma Workshop

September 27, 2018

The Histone Mutated Midline Glioma Workshop was led by NCI-CONNECT. Participants discussed the definition of the disease in adults, current clinical care and treatments, biological targets and clinical trial designs for histone midline gliomas. Participants recognized that accurately diagnosing histone midline gliomas is critical for treatment and research. The group concluded that all tumors should be sampled, processed, analyzed, and stored as standard of care to better understand this rare cancer.

Read the meeting summary >

Oligodendroglioma Workshop

November 19, 2018

The Oligodendroglioma Workshop was led by NCI-CONNECT. Participants discussed the molecular pathology of oligodendrogliomas, clinical trial efficacy endpoints and preclinic models, and collaborative efforts in data sharing. Participants recognized the need to combine data, resources, and samples to develop better treatments for oligodendrogliomas.

Read the meeting summary >

Medulloblastoma Workshop

November 25, 2019 

The Adult Medulloblastoma Workshop was led by NCI-CONNECT. Participants convened to review advances in research, share scientific insights, and discuss clinical challenges in adult medulloblastoma. Participants identified opportunities for collaboration; discussed plans to create a working group of clinicians, researchers, and patient advocates; and developed specific action items to expedite progress in adult medulloblastoma.

Read the meeting summary >

Ependymoma Workshop

February 20-22, 2019 

The Fourth Biennial Ependymoma Consensus was led by Kenneth Aldape, M.D., chief of NCI’s Center for Cancer Research, Laboratory of Pathology. Participants discussed the latest in grading and diagnosing ependymoma, molecular and genetic testing, and clinical care and treatments for ependymoma. Participants discussed the increasing complexity of diagnosing ependymoma, underscoring the need to work together to further define genetic differences in ependymoma tumors and how they are treated.

Read the meeting summary >

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Meetings was originally published by the National Cancer Institute.”